Intra-Cellular Therapies (ITCI) Prices 11.67M Share Common Offering at $30/Sh

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced the pricing of its previously announced underwritten public offering of 11,666,667 shares of its common stock at a public offering price of $30.00 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $350 million from the offering of an aggregate of 11,666,667 shares before deducting underwriting discounts and commissions and offering expenses. Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1,750,000 shares on the same terms and conditions. The offering is expected to close on September 15, 2020, subject to the satisfaction of customary closing conditions.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, SVB Leerink LLC and Evercore Group L.L.C. are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. and Canaccord Genuity LLC are acting as co-lead managers for the offering.

You May Also Be Interested In

• enCore Energy launches $250M at-the-market share offering
• Rocket Lab replaces ATM equity program, eyes Iridium acquisition funding
• Dyadic International raises $2.9M via stock offering and warrants